Innate Pharma (IPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Innate Pharma (IPH) has a cash flow conversion efficiency ratio of 0.995x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-21.59 Million ≈ $-25.24 Million USD) by net assets (€-21.70 Million ≈ $-25.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Innate Pharma's balance sheet to measure how much of total assets are equity-financed.
Innate Pharma - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Innate Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Innate Pharma (IPH) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Innate Pharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innate Pharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chegg Inc
NYSE:CHGG
|
0.034x |
|
Wellspire Holdings Berhad
KLSE:0271
|
-0.129x |
|
Seoyon Co Ltd
KO:007860
|
0.053x |
|
Orian Sh.M. Ltd
TA:ORIN
|
0.107x |
|
RheinLand Holding AG
DU:RLV
|
N/A |
|
Daesung Eltec Co. Ltd
KQ:025440
|
0.061x |
|
Prospect Resources Ltd
AU:PSC
|
-0.090x |
|
DIRTT Environmental Solutions Ltd.
TO:DRT
|
-0.155x |
Annual Cash Flow Conversion Efficiency for Innate Pharma (2005–2025)
The table below shows the annual cash flow conversion efficiency of Innate Pharma from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Innate Pharma market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €-21.70 Million ≈ $-25.37 Million |
€-52.76 Million ≈ $-61.68 Million |
2.431x | +411.38% |
| 2024-12-31 | €8.83 Million ≈ $10.33 Million |
€-6.90 Million ≈ $-8.06 Million |
-0.781x | -24.44% |
| 2023-12-31 | €51.90 Million ≈ $60.68 Million |
€-32.56 Million ≈ $-38.06 Million |
-0.627x | -77.35% |
| 2022-12-31 | €54.15 Million ≈ $63.31 Million |
€-19.15 Million ≈ $-22.39 Million |
-0.354x | +34.99% |
| 2021-12-31 | €107.44 Million ≈ $125.61 Million |
€-58.46 Million ≈ $-68.34 Million |
-0.544x | -63.81% |
| 2020-12-31 | €155.97 Million ≈ $182.35 Million |
€-51.81 Million ≈ $-60.57 Million |
-0.332x | -306.78% |
| 2019-12-31 | €217.42 Million ≈ $254.18 Million |
€34.92 Million ≈ $40.83 Million |
0.161x | +182.58% |
| 2018-12-31 | €167.24 Million ≈ $195.52 Million |
€-32.53 Million ≈ $-38.03 Million |
-0.195x | +65.21% |
| 2017-12-31 | €85.96 Million ≈ $100.49 Million |
€-48.06 Million ≈ $-56.19 Million |
-0.559x | -30.74% |
| 2016-12-31 | €86.17 Million ≈ $100.74 Million |
€-36.85 Million ≈ $-43.08 Million |
-0.428x | -114.82% |
| 2015-12-31 | €72.07 Million ≈ $84.25 Million |
€207.91 Million ≈ $243.07 Million |
2.885x | +1287.24% |
| 2014-12-31 | €74.63 Million ≈ $87.25 Million |
€-18.13 Million ≈ $-21.20 Million |
-0.243x | +10.74% |
| 2013-12-31 | €40.29 Million ≈ $47.10 Million |
€-10.97 Million ≈ $-12.82 Million |
-0.272x | +39.28% |
| 2012-12-31 | €23.36 Million ≈ $27.31 Million |
€-10.47 Million ≈ $-12.25 Million |
-0.448x | -191.92% |
| 2011-12-31 | €26.62 Million ≈ $31.13 Million |
€12.99 Million ≈ $15.18 Million |
0.488x | +221.55% |
| 2010-12-31 | €33.52 Million ≈ $39.18 Million |
€-13.45 Million ≈ $-15.72 Million |
-0.401x | -218.54% |
| 2009-12-31 | €47.12 Million ≈ $55.09 Million |
€-5.94 Million ≈ $-6.94 Million |
-0.126x | +64.67% |
| 2008-12-31 | €41.34 Million ≈ $48.33 Million |
€-14.74 Million ≈ $-17.23 Million |
-0.357x | -90.56% |
| 2007-12-31 | €49.61 Million ≈ $57.99 Million |
€-9.28 Million ≈ $-10.85 Million |
-0.187x | -3029.85% |
| 2006-12-31 | €56.37 Million ≈ $65.90 Million |
€360.00K ≈ $420.88K |
0.006x | +101.77% |
| 2005-12-31 | €20.07 Million ≈ $23.46 Million |
€-7.25 Million ≈ $-8.47 Million |
-0.361x | -- |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated t… Read more